{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:33:23Z","timestamp":1772825603847,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40273-024-01358-y","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:02:44Z","timestamp":1706788964000},"page":"569-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-430X","authenticated-orcid":false,"given":"Shih-Wen","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Shapouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Paris\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bercaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"9844","key":"1358_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/s0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(12)60605-9.","journal-title":"Lancet"},{"issue":"10091","key":"1358_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298\u2013310. https:\/\/doi.org\/10.1016\/s0140-6736(16)32407-2.","journal-title":"Lancet"},{"key":"1358_CR3","unstructured":"National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ\u00ae), Health Professional Version. 2022. Available from: https:\/\/www.cancer.gov\/types\/lymphoma\/hp\/adult-nhl-treatment-pdq. [Accessed 6 Dec 2022]."},{"issue":"3","key":"1358_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316\u201327. https:\/\/doi.org\/10.1002\/ajh.25696.","journal-title":"Am J Hematol"},{"key":"1358_CR5","unstructured":"US Food and Drug Administration. FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns. 2022. Available from: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-withdrew-its-approval-cancer-medicine-ukoniq-umbralisib-due-safety-concerns. [Accessed 1 Jun 2022]."},{"key":"1358_CR6","unstructured":"Gilead Inc. Gilead Statement on Zydelig\u00ae US indication for follicular lymphoma and small lymphocytic leukemia. 2022. Available from: https:\/\/www.gilead.com\/news-and-press\/company-statements\/gilead-statement-on-zydelig-us-indication-for-follicular-lymphoma-and-small-lymphocytic-leukemia. [Accessed 18 Aug 2023]."},{"key":"1358_CR7","unstructured":"Secura Bio Inc. Secura Bio announces Copiktra\u00ae (duvelisib) strategic focus on T-cell lymphoma and voluntary U.S. withdrawal of the relapsed or refractory follicular lymphoma indication. 2021. Available from: https:\/\/www.prnewswire.com\/news-releases\/secura-bio-announces-copiktra-duvelisib-strategic-focus-on-t-cell-lymphoma-and-voluntary-us-withdrawal-of-the-relapsed-or-refractory-follicular-lymphoma-indication-301436834.html. [Accessed 18 Aug 2023]."},{"key":"1358_CR8","unstructured":"Bayer HealthCare Pharmaceuticals Inc. ALIQOPA\u2122 (copanlisib): highlights of prescribing information. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209936s010lbl.pdf. [Accessed 18 Apr 2022]."},{"key":"1358_CR9","unstructured":"Epizyme Inc. TAZVERIK (tazemetostat) tablets: highlights of prescribing information. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf. [Accessed 18 Apr 2022]."},{"key":"1358_CR10","unstructured":"Kite Pharma Inc. YESCARTA\u00ae (axicabtagene ciloleucel): highlights of prescribing information. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf. [Accessed 18 Apr 2022]."},{"key":"1358_CR11","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH\u00ae (tisagenlecleucel): highlights of prescribing information. 2022. Available from: https:\/\/www.fda.gov\/media\/107296\/download?attachment. [Accessed 1 Jun 2022]."},{"key":"1358_CR12","unstructured":"National Institute for Health and Care Excellence. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TA892]. National Institute for Health and Care Excellence,, London, UK. 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ta892. [Accessed 18 Aug 2023]."},{"issue":"7","key":"1358_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74. https:\/\/doi.org\/10.1038\/s41408-020-00340-z.","journal-title":"Blood Cancer J"},{"issue":"23","key":"1358_CR14","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322. https:\/\/doi.org\/10.1200\/jco.2014.59.7534.","journal-title":"J Clin Oncol"},{"key":"1358_CR15","unstructured":"US FDA. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. 2022. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma. [Accessed 27 Oct 2023]."},{"key":"1358_CR16","unstructured":"Genentech Inc. LUNSUMIO\u2122 (mosunetuzumab-axgb): highlights of prescribing information. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf. [Accessed 3 Jan 2023]."},{"issue":"8","key":"1358_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(22)00335-7.","journal-title":"Lancet Oncol"},{"key":"1358_CR18","unstructured":"United States Bureau of Labor Statistics. Consumer price index for all urban consumers: medical care (CUSR0000SAM). 2022. Available from: https:\/\/www.bls.gov\/data\/. [Accessed 5 Dec 2022]."},{"issue":"1","key":"1358_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis: principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health."},{"key":"1358_CR20","unstructured":"US Census Bureau. 2017 national population projections datasets, Table 1. Projected population by single year of age, sex, race, and hispanic origin for the United States: 2016 to 2060. Available from: https:\/\/www.census.gov\/content\/census\/en\/data\/datasets\/2017\/demo\/popproj\/2017-popproj.html. [Accessed 6 Dec 2022]."},{"key":"1358_CR21","unstructured":"SEER. Non-Hodgkin lymphoma: people alive with cancer (U.S. prevalence) on January 1, 2019. 2019. Available from: https:\/\/seer.cancer.gov\/explorer\/application.html. [Accessed 6 Dec 2022]."},{"issue":"4","key":"1358_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.15149","volume":"184","author":"BK Link","year":"2019","unstructured":"Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660\u20133. https:\/\/doi.org\/10.1111\/bjh.15149.","journal-title":"Br J Haematol"},{"issue":"4","key":"1358_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.18553\/jmcp.2019.18259","volume":"25","author":"S Appukkuttan","year":"2019","unstructured":"Appukkuttan S, Yaldo A, Gharibo M, Babajanyan S, Duchesneau E, Zichlin ML, et al. A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States. J Manag Care Spec Pharm. 2019;25(4):437\u201346. https:\/\/doi.org\/10.18553\/jmcp.2019.18259.","journal-title":"J Manag Care Spec Pharm"},{"key":"1358_CR24","unstructured":"Unpublished data on file, Genentech Inc., 2023"},{"issue":"1","key":"1358_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. https:\/\/doi.org\/10.1186\/1471-2288-5-13.","journal-title":"BMC Med Res Methodol"},{"key":"1358_CR26","unstructured":"AnalySource\u00ae. Reprinted with permission by First Databank, Inc. All rights reserved. 2023. Available from: https:\/\/www.analysource.com\/. [Accessed 10 Mar 2023]."},{"key":"1358_CR27","unstructured":"Genentech Inc. RITUXAN\u00ae (rituximab) injection: highlights of prescribing information. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5464lbl.pdf. [Accessed 18 Apr 2022]."},{"key":"1358_CR28","unstructured":"Genentech Inc. GAZYVA\u00ae (obinutuzumab): highlights of prescribing information. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125486s029lbl.pdf. [Accessed 18 Apr 2022]."},{"key":"1358_CR29","unstructured":"Teva Pharmaceuticals USA Inc. BENDEKA\u00ae (bendamustine hydrochloride injection): highlights of prescribing information. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208194s000lbl.pdf. [Accessed 18 Apr 2022]."},{"key":"1358_CR30","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule. 2022. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview. [Accessed 23 Jan 2024]."},{"issue":"1","key":"1358_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/13696998.2021.1901721","volume":"24","author":"R Liu","year":"2021","unstructured":"Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24(1):458\u201368. https:\/\/doi.org\/10.1080\/13696998.2021.1901721.","journal-title":"J Med Econ"},{"issue":"2","key":"1358_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0.","journal-title":"Nat Med"},{"key":"1358_CR33","unstructured":"HCUP Fast Stats. Trends in inpatient stays. 2020. Available from: https:\/\/datatools.ahrq.gov\/hcup-fast-stats\/?type=tab&tab=hcupfseds. [Accessed 5 Dec 2022]."},{"issue":"6","key":"1358_CR34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","volume":"5","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695\u2013705. https:\/\/doi.org\/10.1182\/bloodadvances.2020003531.","journal-title":"Blood Adv"},{"key":"1358_CR35","unstructured":"Genentech Inc. ACTEMRA\u00ae (tocilizumab): highlights of prescribing information. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf. [Accessed 10 Dec 2022]."},{"key":"1358_CR36","unstructured":"Centers for Medicare & Medicaid Services. Clinical Diagnostic Laboratory Fee Schedule. 2022. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files. [Accessed 23 Jan 2024]."},{"key":"1358_CR37","unstructured":"April 2023 Medicare Part B Drug and Biological Average Sales Price Quarterly Payment files. 2023. Available from: https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2023-asp-drug-pricing-files. [Accessed 14 Dec 2023]."},{"key":"1358_CR38","unstructured":"April 2023 Addendum B. OPPS Payment by HCPCS Code for CY 2023. 2023. Available from: https:\/\/www.cms.gov\/medicare\/medicare-fee-service-payment\/hospitaloutpatientpps\/addendum-and-addendum-b-updates\/april-2023. [Accessed 19 Dec 2023]."},{"key":"1358_CR39","unstructured":"US Census Bureau. 2023 population projections for the nation by age, sex, race, Hispanic origin and nativity. Available from: https:\/\/www.census.gov\/newsroom\/press-kits\/2023\/population-projections.html. [Accessed 4 Dec 2023]."},{"key":"1358_CR40","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C et al. SEER Cancer Statistics Review (CSR) 1975-2014. Cancer prevalence tables, January 1, 2014. 2017. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2014\/. [Accessed 12 Dec 2023]."},{"key":"1358_CR41","unstructured":"Fulton Z, Dandamudi N. Epidemiology: follicular lymphoma. In: NHL. Follicular lymphoma forecast and market analysis to 2025. Available from: https:\/\/pharmastore.informa.com\/product\/nhl-follicular-lymphoma\/. [Accessed 12 Dec 2023]."},{"issue":"5","key":"1358_CR42","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","volume":"7","author":"KC Potnis","year":"2023","unstructured":"Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv. 2023;7(5):801\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2022008097.","journal-title":"Blood Adv"},{"key":"1358_CR43","unstructured":"Memorial Sloan Kettering Cancer Center. CAR T cell therapy: a guide for adult patients & caregivers. 2023. Available from: https:\/\/www.mskcc.org\/cancer-care\/patient-education\/car-cell-therapy-guide-adult-patients-caregivers. [Accessed 30 Nov 2023]."},{"issue":"9","key":"1358_CR44","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40273-020-00919-1","volume":"38","author":"SK Cho","year":"2020","unstructured":"Cho SK, Manzoor BS, Sail KR, Paris\u00e9 H, Ravelo A, Shapouri S, et al. Budget impact of 12-month fixed treatment duration venetoclax in combination with obinutuzumab in previously untreated chronic lymphocytic leukemia patients in the United States. Pharmacoeconomics. 2020;38(9):941\u201351. https:\/\/doi.org\/10.1007\/s40273-020-00919-1.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1358_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.18553\/jmcp.2020.20330","volume":"27","author":"S Appukkuttan","year":"2021","unstructured":"Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2021;27(2):166\u201374. https:\/\/doi.org\/10.18553\/jmcp.2020.20330.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1358_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/13696998.2020.1867470","volume":"24","author":"B Cai","year":"2021","unstructured":"Cai B, Zhou ZY, Xue W, Hazra NC, Singh M, Mishra D, et al. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States. J Med Econ. 2021;24(1):131\u20139. https:\/\/doi.org\/10.1080\/13696998.2020.1867470.","journal-title":"J Med Econ"},{"issue":"1","key":"1358_CR47","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jval.2021.11.288","volume":"25","author":"S Liu","year":"2022","unstructured":"Liu S, Yang K, Carter J, Zimmerman T, Tang B. POSA145 budget impact of zanubrutinib to treat relapsed or refractory marginal zone lymphoma from a payer perspective in the United States. Value Health. 2022;25(1):S62. https:\/\/doi.org\/10.1016\/j.jval.2021.11.288.","journal-title":"Value Health."},{"issue":"Suppl 1","key":"1358_CR48","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1182\/blood-2022-157758","volume":"140","author":"KR Davies","year":"2022","unstructured":"Davies KR, Kamalakar R, Yu J, Huang Y, Wang A, Sail K, et al. Health care resource utilization and costs of CAR T therapy in patients with large B-cell lymphoma: a retrospective US claims database analysis. Blood. 2022;140(Suppl 1):5058\u20139. https:\/\/doi.org\/10.1182\/blood-2022-157758.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1358_CR49","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1182\/blood-2023-186548","volume":"142","author":"OO Oluwole","year":"2023","unstructured":"Oluwole OO, Ray MD, Zur R, Little A, Ferrufino C, Doble B, et al. Cost-effectiveness of axicabtagene ciloleucel versus mosunetuzumab in relapsed\/refractory follicular lymphoma in the US. Blood. 2023;142(Suppl 1):5082. https:\/\/doi.org\/10.1182\/blood-2023-186548.","journal-title":"Blood"},{"issue":"7","key":"1358_CR50","doi-asserted-by":"publisher","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","volume":"28","author":"SJ Keating","year":"2022","unstructured":"Keating SJ, Gu T, Jun MP, McBride A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022;28(7):404.e1-6. https:\/\/doi.org\/10.1016\/j.jtct.2022.03.021.","journal-title":"Transplant Cell Ther."},{"key":"1358_CR51","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1080\/10428194.2022.2060503","volume":"63","author":"RT Maziarz","year":"2022","unstructured":"Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, et al. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Leuk Lymphoma. 2022;63:2052\u201362. https:\/\/doi.org\/10.1080\/10428194.2022.2060503.","journal-title":"Leuk Lymphoma"},{"key":"1358_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1182\/blood-2023-173692","volume":"142","author":"SJ Schuster","year":"2023","unstructured":"Schuster SJ, Sehn LH, Bartlett NL, Matasar M, Assouline S, Giri P, et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study. Blood. 2023;142:603. https:\/\/doi.org\/10.1182\/blood-2023-173692.","journal-title":"Blood"},{"key":"1358_CR53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Chavez JC, Sehgal A, Epperla N, Ulrickson ML, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2023021243.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1358_CR54","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1182\/blood-2023-174914","volume":"142","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, et al. Axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial. Blood. 2023;142(Suppl 1):4868. https:\/\/doi.org\/10.1182\/blood-2023-174914.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1358_CR55","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood-2023-180936","volume":"142","author":"SJ Schuster","year":"2023","unstructured":"Schuster SJ, Fowler N, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, et al. Clinical outcomes of patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 Elara 3-year follow-up. Blood. 2023;142(Suppl 1):601. https:\/\/doi.org\/10.1182\/blood-2023-180936.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1358_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood-2022-158631","volume":"140","author":"JP Leonard","year":"2022","unstructured":"Leonard JP, Trneny M, Offner F, Mayer J, Zhang H, Nowakowski GS, et al. Five-year results and overall survival update from the phase 3 randomized study augment: lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with relapsed\/refractory indolent non-Hodgkin lymphoma. Blood. 2022;140(Suppl. 1):561\u20133. https:\/\/doi.org\/10.1182\/blood-2022-158631.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1358_CR57","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1182\/blood-2023-186842","volume":"142","author":"JG Gribben","year":"2023","unstructured":"Gribben JG, Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Kanters S, et al. An updated comparison of clinical outcomes from 4-year follow-up of Zuma-5 (axicabtagene ciloleucel) and the international Scholar-5 external control cohort in relapsed\/refractory follicular lymphoma. Blood. 2023;142(Suppl. 1):4869. https:\/\/doi.org\/10.1182\/blood-2023-186842.","journal-title":"Blood"},{"key":"1358_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"30","key":"1358_CR59","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS Study. J Clin Oncol. 2015;33(30):3467\u201374. https:\/\/doi.org\/10.1200\/JCO.2014.59.2139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1358_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(15)00447-7.","journal-title":"Lancet Oncol"},{"issue":"17","key":"1358_CR61","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/jco.2009.26.5827","volume":"28","author":"MH van Oers","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853\u20138. https:\/\/doi.org\/10.1200\/jco.2009.26.5827.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1358_CR62","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393. https:\/\/doi.org\/10.1016\/s1470-2045(16)30097-3.","journal-title":"Lancet Oncol"},{"key":"1358_CR63","unstructured":"Center for Drug Evaluation and Research (CDER). NDA\/BLA multi\u2010disciplinary review and evaluation 213400 - Tazverik (tazemetostat). 2019."},{"key":"1358_CR64","unstructured":"Celgene Corporation. REVLIMID (lenalidomide): highlights of prescribing information. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021880s057lbl.pdf. [Accessed 18 Apr 2022]."},{"key":"1358_CR65","unstructured":"Bristol Myers Squibb. R2 revlimid\/rituximab promotional brochure. 2021. Available from: https:\/\/media.revlimidhcp.com\/wp-content\/uploads\/2021\/11\/R2-Efficacy.pdf. [Accessed 23 Jan 2024]."},{"issue":"1","key":"1358_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s1470-2045(21)00591-x","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103. https:\/\/doi.org\/10.1016\/s1470-2045(21)00591-x.","journal-title":"Lancet Oncol"},{"key":"1358_CR67","unstructured":"US FDA. Multi-disciplinary review and evaluation. BLA 125643\/394 clinical review and evaluation: Yescarta (axicabtagene ciloleucel). 2022. Available from: https:\/\/fda.report\/media\/157687\/April-1-2022-Clinical-Review-and-Evaluation-YESCART_0.pdf. [Accessed 23 Jan 2024]."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01358-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01358-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01358-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T05:09:37Z","timestamp":1713848977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01358-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01358-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"14 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The design, study conduct, and financial support for the study were provided by F. Hoffmann-La Roche Ltd. and Genentech, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Shih-Wen Lin, Sheila Shapouri, Mei Wu, and Eunice Kim are employees of Genentech, Inc. and may own stocks\/and or options from F. Hoffmann-La Roche Ltd. H\u00e9l\u00e8ne Paris\u00e9 and Eric Bercaw are employees of Medicus Economics, LLC and received consulting fees for research from Genentech, Inc. Matthew Matasar is an employee of the Rutgers Cancer Institute of New Jersey. He has appointments for consultancy or is an advisory board member to Genentech, Inc., F. Hoffmann-La Roche Ltd, Bayer, Juno, Seattle Genetics, Takeda, Teva, and Merck; has institutional research funding from Genentech, Inc., F. Hoffmann-La Roche Ltd, Bayer, GM Biosciences, Immunovaccine Technologies, Janssen, Pharmacyclics, and Seattle Genetics; has received honoraria or stipends from Genentech, Inc., F. Hoffmann-La Roche Ltd, ADC Therapeutics, AstraZeneca, Bayer, BMS, Celgene, Epizyme, Immunovaccine Technologies, IMV Therapeutics, Janssen, Kite, Pharmacyclics, Regeneron, Seagen, Seattle Genetics, Takeda, and Teva; and he owns stocks\/and or options from Merck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available in this article. The model is not publicly available because of its intrinsic commercial value and cannot be shared for legal reasons.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Genentech, Inc. and Medicus Economics, LLC participated in the design of the research, the analysis and interpretation of finding, and in the manuscript writing, review, and approval. All authors contributed to the development of the manuscript and maintained control over the final content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}